It's Good For A 216% Gain...

-------------Sponsor-------------
Where Can You Turn $300 Into $1.3 Million Right Now?

Our own small-company specialist, Robert Morris, has found a way to 'sniff out' tiny penny stocks on the verge of a major breakout.  And the timing for this has never been better.

You see, the system takes advantage of an obscure SEC regulation that sends penny stock prices through the roof.

We've seen some stocks gain 852%... 5,450%... even 17,496% in no time flat.

Click here for the details...
-----------------------------------

ITMN is developing pirfenidone for a chronic lung disease called idiopathic pulmonary fibrosis.  The often fatal disease affects over 5 million people worldwide.  And, there’s no cure or satisfactory treatment.

This wasn’t an “official” trade in the service, anyone could have bought the stock for themselves.  I know many of you bought shares for your own account.

Congratulations to all of you who moved quickly and scooped up these shares!  You’re now sitting on a huge profit!

Take a look at what the stock’s done lately…


The shares skyrocketed over the last week on news the FDA advisory committee voted 9-to-3 to recommend approval of the lung cancer drug.

Investors are clearly excited over the potential that pirfenidone holds.

When I wrote about ITMN, it was trading around $13 per share.  Today, the shares have already traded as high as $41.20.  That’s good for a 216% gain!

A day after the news on pirfenidone was released, two “Wall Street” investment banks upgraded their research rankings on the company.

This helped propel the stock even higher.

All in all, this trade worked out just like we thought it would.  We identified the key drug with a rapidly approaching milestone.  We found the company that owned the drug and took a position in the stock early.

This allowed us to get in at rock bottom prices.

Despite questions about research results and efficacy, the drug passed through the FDA gauntlet and received the recommendation of approval. News of the successful run caused the stock to rocket higher.

It’s not a bad two month trade if you ask me.

Now that most of the gain has been captured, the risk reward profile on the stock has changed.  No sense giving up our big gains, just to collect pennies of upside.

Now’s the time to lock in our big gain… it’s never a bad idea.

While InterMune may be on the path to bigger and better things, it’s time for us to say goodbye to this pick!

***Editor’s Note*** If you’d like more stock ideas in the biotechnology sector with this kind of potential, you should take a look at Robert’s Biotech Supertrader service.

There are now a number of stocks in the portfolio that are awaiting news from the FDA.  If that news is positive, you know what could happen to these stocks!  Click here to get the details…

 Print Page                                                   Bookmark Us